We would love to hear your thoughts about our site and services, please take our survey here.
Looking forward to the siRNA news now. It could provide the perfect compliment to getting the US patent secured.
The ground work has been done (albeit slowly at the expense of the SP) and the hard work could now pay off for N4P. There’s such a buzz around siRNA / mRNA delivery atm, perfect timing perhaps.
Great news re us US patent.
John Chiplin also recently resigned from his board role at Scancell (earlier in year) so looks like he is stepping back from his corporate roles.
We have touched the low from back in Feb 2016. Battered market sentiment for small caps atm matched with N4P making progress (last 2 rns'es), albeit slower than the market would like. Yes commercial traction is needed but this price could turn out to be steal of the century IF the company can soon deliver.
DYOR
Post courtesy of Luke on Telegram. Think he has it spot on:
Added, no brainer.
Current valuation barely more than the cash injection received this week!
Nothing for current cash 8-10m,
nothing for production deal,
nothing for 4/5 existing discovers waiting to be progressed,
nothing for the upcoming drill ( velo),
nothing for further #120 m financing for more prod deals/ partnerships/ drills and further exploration .
..oh nothing for Malaysian
venture... could go on.......